For research use only. Neither BPC-157 nor TB-500 are FDA-approved for human use. All content is intended for educational and laboratory research purposes. Not for human consumption.
Overview: Why Researchers Co-Study BPC-157 and TB-500
In preclinical research, BPC-157 and TB-500 have become two of the most co-investigated synthetic peptides due to their complementary biological profiles. Separately, each compound has generated substantial peer-reviewed literature. Together, they are studied in the context of tissue repair biology, angiogenesis, and inflammatory pathway research — making this combination a popular focus for laboratories examining musculoskeletal and wound healing models.
The pairing has become colloquially known in research communities as the “Wolverine Stack,” named for its association with accelerated healing biology in animal models. This article summarizes the scientific rationale for studying these compounds together.
Individual Mechanisms Under Study
BPC-157
Research on BPC-157 has highlighted its interaction with nitric oxide pathways, FAK-paxillin signaling, and VEGFR2 upregulation. In animal models, it has been studied in the context of tendon reattachment, GI tract ulceration, and neural pathway modulation. Its effects in preclinical models appear localized to the site of study.
TB-500
TB-500 is a fragment of Thymosin Beta-4 that influences actin dynamics and cell motility. Research has focused on its role in promoting angiogenesis and progenitor cell activation across broader tissue regions. Its effects in preclinical models appear more systemic compared to BPC-157.
Complementary Research Profiles
| Research Parameter | BPC-157 | TB-500 |
|---|---|---|
| Primary signaling focus | NO system, FAK-paxillin, VEGFR2 | Actin regulation, progenitor cells |
| Effect distribution | Localized (site-specific) | Systemic |
| GI research models | Extensive literature | Limited |
| Cardiac/vascular models | Some literature | Substantial literature |
| Angiogenesis focus | Moderate | Primary focus area |
Laboratory Handling When Studying Both Compounds
Both BPC-157 and TB-500 are supplied as lyophilized powders. Researchers should reconstitute each peptide separately with bacteriostatic water and never combine them in a single vial, as this can compromise stability and confound experimental results. Store reconstituted solutions at 2–8°C and lyophilized stock at -20°C. Strict sterile technique is essential for all preparation steps.
Availability at Iron Labs
Iron Labs supplies both BPC-157 and TB-500 as individual research-grade compounds with third-party COA documentation. We also carry a BPC-157 + TB-500 research blend for laboratories studying these peptides in combination. All products include HPLC purity data and mass spec identity confirmation.
Source BPC-157 and TB-500 for your lab → Iron Labs Research Catalog
Regulatory Notice
BPC-157 and TB-500 are not approved by the FDA for any human or veterinary use. These compounds are sold by Iron Labs strictly as research chemicals for use in laboratory settings. No therapeutic claims are made or implied. This content is for educational purposes only.